2009) and in hypertensive Dahl salt‐sensitive rat (Yu et al. 2003), GLP‐1 agonists have been shown to reduce MAP. In this study, the treatment is acute using native GLP‐1. It is possible that a longer treatment period or another hypertensive model would have revealed a reduced MAP. In a human study acute treatment with liraglutide significantly increased diastolic and systolic blood pressure in patients with T2DM (Skov et al. 2016). Here, GCG is linked to type 2 diabetes mellitus.